Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMV Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRINCETON, N.J., AUG. 14, 2026 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

RICH HEYMAN TO RETIRE FROM PMV PHARMA BOARD OF DIRECTORS; LAURIE STELZER, DIRECTOR SINCE 2020, APPOINTED AS NEW CHAIR RICH HEYMAN TO RETIRE FROM PMV PHARMA BOARD OF DIRECTORS; LAURIE STELZER, DIRECTOR SINCE 2020, APPOINTED AS NEW CHAIR

PMV PHARMACEUTICALS ANNOUNCES BOARD CHAIR TRANSITION

PRINCETON, N.J., MARCH 06, 2026 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER31, 2025, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., OCT. 24, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED UPDATED DATA FROM THE PHASE 2 PIVOTAL PORTION OF THE ONGOING PYNNACLE CLINICAL TRIAL. RESULTS WERE PRESENTED TODAY IN AN ORAL PRESENTATION BY ALISON M. SCHRAM, M.D., MEDICAL ONCOLOGIST AT MEMORIAL SLOAN KETTERING CANCER CENTER AND PYNNACLE STUDY INVESTIGATOR, AT THE 2025AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICSTAKING PLACE IN BOSTON, MASSACHUSETTS. THE ONGOING PHASE 1/2 PYNNACLE CLINICAL TRIAL IS EVALUATING REZATAPOPT IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING A TP53 Y220C MUTATION.

PMV PHARMACEUTICALS ANNOUNCES UPDATED REZATAPOPT MONOTHERAPY INTERIM DATA FROM ONGOING PYNNACLE PHASE 2 TRIAL ACROSS MULTIPLE SOLID TUMORS WITH A TP53 Y220C MUTATION

PRINCETON, N.J., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED INTERIM DATA FROM THE PHASE 2 PIVOTAL PORTION OF THE PYNNACLE CLINICAL TRIAL. THE ONGOING PHASE 1/2 PYNNACLE CLINICAL TRIAL IS EVALUATING REZATAPOPT IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING A TP53 Y220C MUTATION.

PMV PHARMACEUTICALS ANNOUNCES PROMISING REZATAPOPT MONOTHERAPY INTERIM DATA FROM PYNNACLE PHASE 2 TRIAL ACROSS MULTIPLE SOLID TUMORS WITH A TP53 Y220C MUTATION

PRINCETON, N.J., AUG. 07, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., MAY 23, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (PMV PHARMA; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT DAVID H. MACK, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER AND DEEPIKA JALOTA, PHARM. D., CHIEF DEVELOPMENT OFFICER, WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES. MANAGEMENT WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

PMV PHARMACEUTICALS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

ENROLLMENT ON TRACK IN PHASE 2 PIVOTAL PORTION OF PYNNACLE CLINICAL TRIAL EVALUATING REZATAPOPT AS MONOTHERAPY IN PATIENTS WITH TP53 Y220C AND KRAS WILD-TYPE ADVANCED SOLID TUMORS; MORE THAN 90% OF SITES ACTIVATED ACROSS THE U.S., EUROPE, U.K., AND ASIA-PACIFIC; INTERIM ANALYSIS DATA EXPECTED MID-2025 ENROLLMENT COMMENCED IN THE MD ANDERSON CANCER CENTER INVESTIGATOR-INITIATED PHASE 1B STUDY EVALUATING REZATAPOPT MONOTHERAPY AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY AML/MDS HARBORING A TP53 Y220C MUTATION CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $183.3 MILLION AS OF DECEMBER31, 2024 PROVIDING EXPECTED CASH RUNWAY TO END OF 2026 PRINCETON, N.J., MARCH 03, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY CLINICAL-STAGE COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER31, 2024, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., FEB. 11, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT DAVID H. MACK, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER AND DEEPIKA JALOTA, PHARM. D., CHIEF DEVELOPMENT OFFICER, WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES. MANAGEMENT WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

PRINCETON, N.J., MAY 09, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024, AND PROVIDED A CORPORATE UPDATE.

PMV Pharmaceuticals, Inc.

PMVP

Price

Financial Reports

No items found.

Press Releases

PMV Pharmaceuticals, Inc.

PMVP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PMVP